Echoes of a failure: what lessons can we learn?
Mené sur 706 patients atteints d'un mélanome non résécable ou de stade métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout de l'épacadostat au pembrolizumab (durée médiane de suivi : 12,4 mois)
There were high expectations for combining the IDO1 inhibitor epacadostat with pembrolizumab, an anti-PD-1 antibody, based on promising data from a phase 1 trial, which involved just 22 patients with melanoma (12 of whom responded) treated with various doses of epacadostat. The placebo-controlled phase 3 ECHO-301/KEYNOTE-252 trial done by Georgina V Long and colleagues, published in The Lancet Oncology, involving 706 patients with melanoma, was launched to assess if the combination of epacadostat 100 mg orally twice per day with pembrolizumab 200 mg intravenously every 3 weeks was better than pembrolizumab alone. This study was the first phase 3 trial to report results from among a myriad looking for combination regimens that could surpass anti-PD-1 monotherapy in patients with treatment-naive or treatment-refractory melanoma.
The Lancet Oncology , commentaire, 2018